Kurtis Klecan, MD
Family Medicine · Belleville, KSNPI 1154854008
Payments from drug & device makers
Across 194 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$577
- Amgen$430
- AstraZeneca$280
- Paratek Pharmaceuticals, Inc.$228
- Lilly USA, LLC$224
- Novo Nordisk$186
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,958100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $577 |
| Amgen | 32 | $430 |
| AstraZeneca | 18 | $280 |
| Paratek Pharmaceuticals, Inc. | 14 | $228 |
| Lilly USA, LLC | 15 | $224 |
| Novo Nordisk | 12 | $186 |
| Johnson & Johnson | 9 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $97 |
| Bayer | 6 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $58 |
| Electromed, Inc. | 4 | $54 |
| Viatris Specialty LLC | 3 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Pfizer | 3 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Heron Therapeutics, Inc. | 3 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Radius Health, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Mindray DS USA, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Smith+Nephew | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$2,972 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 122 | $61,225 |
| EliquisApixaban | 100 | $53,301 |
| XareltoRivaroxaban | 86 | $41,275 |
| TrulicityDulaglutide | 38 | $38,265 |
| MounjaroTirzepatide | 35 | $37,399 |
| OzempicSemaglutide | 30 | $28,156 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $21,813 |
| JanuviaSitagliptin Phosphate | 32 | $18,676 |
| Repatha SureclickEvolocumab | 19 | $14,736 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,841 |
| MovantikNaloxegol Oxalate | 42 | $12,225 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $12,084 |
| MyrbetriqMirabegron | 43 | $11,669 |
| CreonLipase/Protease/Amylase | 13 | $9,847 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $9,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $224 | $75,66473 claims |
| PfizerEliquis | $38 | $53,301100 claims |
| Johnson & JohnsonXarelto | $119 | $41,27586 claims |
| Novo NordiskOzempic | $186 | $28,15630 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $280 | $28,05058 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $11,66943 claims |
| AbbVieCreon | $577 | $9,84713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Belleville
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.